Short-term statin use prevents contrast-induced acute kidney injury

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway

  • Short term statin treatment in effective in preventing contrast-induced acute kidney injury (CI-AKI) in patients undergoing coronary angiography or percutaneous coronary intervention.

Study design

  • Meta-analysis that included 21 randomized controlled trials involving 7746 patients.
  • The goal was to assess the role of short-term statin treatment in the prevention of CI-AKI and clinical adverse events in patients undergoing coron ary angiography or percutaneous coronary intervention .

Key results
  • Short-term statin treatment significantly reduced the risk of CI-AKI [risk ratio (RR) 0.57; 95 % confident interval (CI) 0.47-0.69; p < 0.00001) and was associated with a lower post-procedural serum creatinine level and a higher estimated glomerular filtra-tion rate.
  • High-dose statins resulted in a lower incidence of CI-AKI than the lower-dose statins.
  • The benefit was seen across subgroups for patients at risk of CI-AKI, statin-naïve patients, and East Asians, regardless of statin type, definition of CI-AKI, use of N-acetylcysteine (NAC) and hydration, and osmolality of contrast.
  • Statin use did not seem to affect the incidence of adverse events.
Limitations
  • Due to the limited study numbers and pop-ulation sizes, the power of the analyses may be restricted.
  • There was significant heterogeneity among studies for some outcomes.
  • Only 1 study reported data on adverse events caused by statins.

Why This Matters

  • Short term statin use appears to prevent the development of CI-AKI in this population and can be considered for patients undergoing these procedures, especially for those at increased risk of this complication.